Breakthrough in Macular Edema Treatment: New Study Paves Way for Affordable Options

Strategic Insights -

Research conducted by Maharaja Agrasen Medical College has made significant strides in finding an effective and affordable treatment for diabetic macular edema (DME). The study, published in the Indian Journal of Pharmacology, investigated the efficacy and safety of biosimilars of bevacizumab, an off-label anti-vascular endothelial growth factor (VEGF) therapy, in treating naive DME patients. The study involved 123 participants with an average log MAR visual acuity of 0.87 ± 0.22 and central retinal thickness at baseline on OCT of 398.5 ± 37.61 mm.

Key Takeaways:

  • The study found that biosimilars of bevacizumab, such as BevaciRelTM and ZyBev, are safe and efficacious in treating DME in a cost-effective manner, with an incremental cost-effectiveness ratio of 10.8.
  • The therapy restored retinal architecture and enhanced vision in DME patients, with a similar improvement in visual acuity across the groups.
  • The cost-effective analysis using a decision-tree analysis model showed that the biosimilars were more affordable than the original medication, Avastin.
  • The study included 69 (59%) men and 54 (41%) women with naive DME, and the cohort had an average log MAR visual acuity of 0.87 ± 0.22.
  • The central retinal thickness at baseline on OCT was 398.5 ± 37.61 mm, and the visual acuity showed a similar improvement across the groups.
  • The study concluded that the biosimilars of bevacizumab are safe and efficacious in treating DME in a cost-effective manner.

Statistics:

  • 123 participants with naive DME were included in the study.
  • 69 (59%) were men and 54 (41%) were women.
  • The average log MAR visual acuity was 0.87 ± 0.22.
  • The central retinal thickness at baseline on OCT was 398.5 ± 37.61 mm.
  • The visual acuity showed a similar improvement across the groups.
  • The incremental cost-effectiveness ratio was 10.8.

Sources:

  • Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in naive patients with diabetic macular edema. Indian Journal of Pharmacology, 2024,56(4).
  • NewsRx. Research Study Findings from Maharaja Agrasen Medical College Update Understanding of Macular Edema (Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in naive patients with diabetic macular edema). Immunotherapy Weekly. September 25, 2024; p 200.